Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
Clinicaltrials.gov identifier:
NCT05572684
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
Study Contact Information:
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
About the Study
NOTE: This study is no longer recruiting people.
This study will test the safety and effectiveness of a new drug called NC410 used in combination with the agent Keytruda (pembrolizumab) in people with advanced or cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:
- have a tumor marker known as microsatellite stable (MSS), OR
- have been treated with and no longer respond to treatment with drugs known as immune checkpoint inhibitors.
NOTE: This study is no longer recruiting people.
NOTE: This study is no longer recruiting people.